For today’s episode we will be reviewing three more articles from the Jan-Feb 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to https://college.acaai.org/allergytalk

Article Links:

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.

Altered Viscosity of Nasal Secretions in Postnasal Drip.

Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: [email protected]

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.